Molidustat shows activity against certain colorectal cancer cells
The drug Molidustat may work by inhibiting both GSTP1 and PHD2 in APC-mutant colorectal cancer.
Molidustat induced cell death in human APC-mutant colorectal cancer (CRC) cells. This drug is a prolyl hydroxylase domain (PHD) inhibitor.
Researchers used thermal proteome profiling and chemical proteomics to study the drug. They identified glutathione S-transferase P1 (GSTP1) as an off-target of Molidustat. This off-target engagement of GSTP1 contributes to the anti-tumour activity of Molidustat.
Ablation of PHD2 alone did not affect cell viability. However, combined loss of PHD2 and GSTP1 induced synergistic proteomic changes. These changes are associated with cell-cycle suppression and apoptotic signalling.
Integrated proteomic and metabolomic analyses revealed energetic and metabolic perturbations. These perturbations are specific to simultaneous GSTP1 and PHD2 loss. APC-mutant mouse organoids displayed selective sensitivity to Molidustat.
The results suggest a synthetic lethal interaction between GSTP1 and PHD2 in APC-mutant contexts. This identifies a functional interaction between GSTP1 and PHD2 in a subset of CRC.
Key facts
- Molidustat is a PHD2 inhibitor that also inhibits GSTP1.
- The combined loss of PHD2 and GSTP1 induces cell death in APC-mutant CRC cells.
- APC mutations are a defining feature of colorectal cancer.